Dyslipidaemia is defined as an abnormal amount of lipid(s) (triglycerides (>200), Low Density Lipoproteins (LDL) (>130), cholesterol (>240mg/dL) and High Density Lipoproteins (HDL) (<40mg/dL male / <50mg/dL female) within the blood.  Many patients meet the requirements of dyslipidaemia on more than one factor.

This report provides the current prevalent population for Dyslipidaemia across 12 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Russia, Brazil, Japan, India and China) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of Dyslipidaemia have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Dyslipidaemia is associated with increased risk of cardiovascular events including:

  • Stroke
  • DVT
  • Metabolic syndrome
  • Heart failure
  • T2DM
  • Atherosclerosis
  • Peripheral arterial disease
  • Coronary Artery Disease
  • Myocardial Infarction
  • Elevated C-Reactive Protein

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

  • Able to quantify patient populations in global Dyslipidaemia market to target the development of future products, pricing strategies and launch plans.
  • Gain further insight into the prevalence of the subdivided types of Dyslipidaemia and identify patient segments with high potential.
  • Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
  • Provide a level of understanding on the impact from specific co-morbid conditions on Dyslipidaemia prevalent population.
  • Identify sub-populations within Dyslipidaemia which require treatment.
  • Gain an understanding of the specific markets that have the largest number of Dyslipidaemia patients.